Postoperative Intensity Modulated Radiation Therapy in High Risk Prostate Cancer: A Dosimetric Comparison

Medical Dosimetry

Volumn 36, Issue 3, 2011, Pages 231-239

  Digesú, Cinzia ^a   Cilla, Savino ^a   De Gaetano, Andrea ^b   Massaccesi, Mariangela ^a   Macchia, Gabriella ^a   Ippolito, Edy ^a   Deodato, Francesco ^a   Panunzi, Simona ^b   Iapalucci, Chiara ^a   Mattiucci, Gian Carlo ^c   D'Angelo, Elisa ^a   Padula, Gilbert D A ^d   Valentini, Vincenzo ^c   Cellini, Numa ^c   Piermattei, Angelo ^a   Morganti, Alessio G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CNR   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d Saint Mary's Health Care   (United States)

Author keywords

IMRT; Postoperative therapy; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PELVIS LYMPH NODE; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC FOSSA; RECTUM; TREATMENT PLANNING;

AGED; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 79960916150     PISSN: 09583947     EISSN: 18734022     Source Type: Journal    
DOI: 10.1016/j.meddos.2010.03.009     Document Type: Article

References (38)

1. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006, 296:2329-2335.
2. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578. European Organization for Research and Treatment of Cancer.
3. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol 2009, 27:2924-2930.
4. Valicenti R.K., Gomella L.G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: The importance of radiation dose. Urology 1998, 52:1034-1040.
5. Cozzarini C., Montorsi F., Fiorino C., et al. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:966-974.
6. Mendenhall W.M., Henderson R.H., Nichols R.C., et al. Postprostatectomy radiotherapy for prostate cancer. Am. J. Clin. Oncol. 2009, (Epub ahead of print).
7. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother. Oncol. 2009, 93:207-212.
8. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neo-adjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 2003, 21:1904-1911. Radiation Therapy Oncology Group 9413.
9. Spiotto M.T., Hancock S.L., King C.R. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:54-61.
10. Abramowitz M.C., Pollack A. Postprostatectomy radiation therapy for prostate cancer. Semin. Radiat. Oncol. 2008, 18:15-22.
11. Ling C.C., Burman C., Chui C.S., et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int. J. Radiat. Oncol. Biol. Phys. 1996, 35:721-730.
12. De Meerleer G.O., Vakaet L.A., De Gersem W.R., et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47:639-648.
13. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity modulated versus conventional radiotherapy using localized fields. Prostate. Cancer. Prostatic. Dis. 2006, 10:82-86.
14. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother. Oncol. 2007, 82:160-166.
15. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose-volume analysis. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:705-712.
16. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:1053-1058.
17. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:1424-1430.
18. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 2006, 176:1415-1419.
19. Cahlon O., Zelefsky M.J., Shippy A., et al. Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:S33.
20. Cahlon O., Hunt M., Zelefsky M.J. Intensity-modulated radiation therapy: Supportive data for prostate cancer. Semin. Radiat. Oncol. 2008, 18:48-57.
21. Bastasch M.D., Teh B.S., Mai W.Y., et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:101-106.
22. Pinkawa M., Siluschek J., Gagel B., et al. Postoperative radiotherapy for prostate cancer: Evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther. Onkol. 2007, 183:23-29.
23. Koontz B.F., Das S., Temple K., et al. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med. Dosim. 2009, 34:256-260.
24. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother. Oncol. 2007, 84:148-155.
25. Cozzarini C., Fiorino C., Di Muzio N., et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother. Oncol. 2007, 84:164-170.
26. Teh B.S., Bastasch M.D., Mai W.Y., et al. Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. Am. J. Clin. Oncol. 2007, 30:395-400.
27. Nath S.K., Sandhu A.P., Rose B.S., et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, (Epub ahead of print).
28. Sanguineti G., Castellone P., Foppiano F., et al. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder. Strahlenther. Onkol. 2004, 180:563-572.
29. Armitage P., Berry G. Statistical Methods in Medical Research 1994, Blackwell Scientific Publication Limited, Oxford.
30. Sidhom M.A., Kneebone A.B., Lehman M., et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother. Oncol. 2008, 88:10-19.
31. Wu Q., Mohan R., Morris M., et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: Dosimetric results. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:573-585.
32. Mangar S.A., Huddart R.A., Parker C.C., et al. Technological advances in radiotherapy for the treatment of localized prostate cancer. Eur. J. Cancer 2005, 41:908-921.
33. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med. Phys. 1999, 26:1100.
34. Burman C., Kutcher G.J., Emami B., et al. Fitting of normal tissue tolerance data to an analytic function. Int. J. Radiat. Oncol. Biol. Phys. 1991, 21:123-135.
35. Muren L.P., Wasbø E., Helle S.I., et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:1034-1041.
36. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:649-656.
37. Liu Y.M., Shiau C.Y., Lee M.L., et al. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:1113-1123.
38. Li X.A., Wang J.Z., Jursinic P.A., et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:1251-1257.